LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

50.5 -1.85

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

50.42

Max

51.57

Galvenie mērījumi
By Trading Economics
Ienākumi	36M -2.3M
Pārdošana	-3.9M 208M
P/E Sektora vidējais	48.435 51.415
EPS	0.208
Peļņas marža	-1.104
Darbinieki	778
EBITDA	-72M 19M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+22.99% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	65M 2.9B
Iepriekšējā atvēršanas cena	52.35
Iepriekšējā slēgšanas cena	50.5

Ziņu noskaņojums

By Acuity

100%

332 / 346 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. maijs 22:44 UTC

Iegādes, apvienošanās, pārņemšana

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

2026. g. 14. maijs 22:27 UTC

Iegādes, apvienošanās, pārņemšana

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

2026. g. 14. maijs 22:12 UTC

Peļņas

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

2026. g. 14. maijs 21:52 UTC

Iegādes, apvienošanās, pārņemšana

LVMH to Sell Marc Jacobs

2026. g. 15. maijs 00:00 UTC

Peļņas

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

2026. g. 14. maijs 23:57 UTC

Iegādes, apvienošanās, pārņemšana

Kakao: Stake Sales Aim to Secure Funds for Future Investments

2026. g. 14. maijs 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

2026. g. 14. maijs 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

2026. g. 14. maijs 23:56 UTC

Tirgus saruna

Gold Prices Rise on Strong Demand -- Market Talk

2026. g. 14. maijs 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

2026. g. 14. maijs 23:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 14. maijs 23:50 UTC

Tirgus saruna

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

2026. g. 14. maijs 23:47 UTC

Peļņas

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

2026. g. 14. maijs 23:47 UTC

Peļņas

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

2026. g. 14. maijs 23:46 UTC

Peļņas

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

2026. g. 14. maijs 23:46 UTC

Peļņas

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

2026. g. 14. maijs 23:28 UTC

Tirgus saruna

New Zealand's Economy Faltering Amid Shocks -- Market Talk

2026. g. 14. maijs 23:00 UTC

Tirgus saruna

Australia's One Nation Party Leads In The Polls -- Market Talk

2026. g. 14. maijs 22:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 14. maijs 22:46 UTC

Tirgus saruna

Court Decision 'Negative But Balanced' for Coles -- Market Talk

2026. g. 14. maijs 22:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 14. maijs 22:35 UTC

Tirgus saruna

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

2026. g. 14. maijs 22:11 UTC

Iegādes, apvienošanās, pārņemšana

LVMH Agrees to Sell Marc Jacobs -- WSJ

2026. g. 14. maijs 22:06 UTC

Tirgus saruna

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

2026. g. 14. maijs 22:04 UTC

Peļņas

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

2026. g. 14. maijs 22:04 UTC

Peļņas

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

2026. g. 14. maijs 22:04 UTC

Peļņas

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

2026. g. 14. maijs 22:00 UTC

Peļņas

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026. g. 14. maijs 21:55 UTC

Peļņas

Nu Holdings 1Q EPS 18c >NU

2026. g. 14. maijs 21:55 UTC

Peļņas

Nu Holdings 1Q Rev $4.97B >NU

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

22.99% augšup

Prognoze 12 mēnešiem

Vidējais 63.17 USD 22.99%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

332 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.